Patents by Inventor Christian Scheffold

Christian Scheffold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combinations for the treatment of cancer
    Patent number: 12673052
    Abstract: The present invention relates to combinations comprising a checkpoint inhibitor and a c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of the free base of Compound 1, as well as crystalline forms of salts of Compound 1, in combination with a checkpoint inhibitor. The invention further relates to methods of treating cancer by administering Compound 1 as a single agent or a combination described herein.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: July 7, 2026
    Assignee: Exelixis, Inc.
    Inventors: Gisela Schwab, Christian Scheffold, Colin Chong, Ssucheng Jeff Hsu, Peter Lamb, Peiwen Yu
  • Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
    Publication number: 20240350477
    Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
    Type: Application
    Filed: July 26, 2023
    Publication date: October 24, 2024
    Inventors: Dana T. Aftab, Gisela Schwab, Colin Hessel, Christian Scheffold, Steven Lacy, Dale Miles, Alan Arroyo, Mark Dean
  • COMBINATIONS FOR THE TREATMENT OF CANCER
    Publication number: 20230301979
    Abstract: The present invention relates to combinations comprising a checkpoint inhibitor and a c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of the free base of Compound 1, as well as crystalline forms of salts of Compound 1, in combination with a checkpoint inhibitor. The invention also relates to pharmaceutical compositions comprising these combinations. The invention further relates to methods of treating cancer by administering Compound 1 as a single agent or a combination described herein.
    Type: Application
    Filed: July 29, 2021
    Publication date: September 28, 2023
    Inventors: Gisela Schwab, Christian Scheffold, Colin Chong, Ssucheng Jeff Hsu, Peter Lamb, Peiwen Yu
  • Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
    Publication number: 20230045783
    Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
    Type: Application
    Filed: September 7, 2021
    Publication date: February 9, 2023
    Inventors: Dana T. Aftab, Gisela Schwab, Colin Hessel, Christian Scheffold, Steven Lacy, Dale Miles, Alan Arroyo, Mark Dean
  • Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
    Publication number: 20220401433
    Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
    Type: Application
    Filed: August 15, 2022
    Publication date: December 22, 2022
    Inventors: Dana T. Aftab, Gisela Schwab, Colin Hessel, Christian Scheffold, Steven Lacy, Dale Miles, Alan Arroyo, Mark Dean
  • Combinations of Cabozantinib and Atezolizumab to Treat Cancer
    Publication number: 20220056138
    Abstract: This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.
    Type: Application
    Filed: November 4, 2021
    Publication date: February 24, 2022
    Inventors: Gisela Schwab, Christian Scheffold, Colin Hessel
  • Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
    Publication number: 20220000857
    Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
    Type: Application
    Filed: September 7, 2021
    Publication date: January 6, 2022
    Inventors: Dana T. Aftab, Gisela Schwab, Colin Hessel, Christian Scheffold, Steven Lacy, Dale Miles, Alan Arroyo, Mark Dean
  • Combinations of cabozantinib and atezolizumab to treat cancer
    Patent number: 11198731
    Abstract: This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: December 14, 2021
    Assignee: Exelixis, Inc.
    Inventors: Gisela Schwab, Christian Scheffold, Colin Hessel
  • Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
    Patent number: 11141413
    Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: October 12, 2021
    Assignee: Exelixis, Inc.
    Inventors: Dana T. Aftab, Gisela Schwab, Colin Hessel, Christian Scheffold, Steven Lacy, Dale Miles, Alan Arroyo, Mark Dean
  • Combinations of Cabozantinib and Atezolizumab to Treat Cancer
    Publication number: 20190352403
    Abstract: This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.
    Type: Application
    Filed: January 19, 2018
    Publication date: November 21, 2019
    Inventors: Gisela Schwab, Christian Scheffold, Colin Hessel
  • Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
    Publication number: 20190209547
    Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
    Type: Application
    Filed: April 17, 2017
    Publication date: July 11, 2019
    Inventors: Dana T. Aftab, Gisela Schwab, Colin Hessel, Christian Scheffold, Steven Lacy, Dale Miles, Alan Arroyo, Mark Dean